Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs

The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption.

COPENHAGEN, Denmark – September 4, 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising product can potentially stabilize the gut of piglets and reduce the severity of post weaning diarrhea (PWD). 

PWD is a major, global swine health challenge caused by E. coli infections in newly weaned pigs. Globally, PWD is estimated to lead to a loss of production of EUR 1-2 billion per year. Additionally, PWD is considered the main driver for antibiotic use in weaner pigs. In Denmark alone, antibiotic consumption among weaners constitutes 49% of the total use of antibiotics in pigs (DANMAP 2021) . 
021*).  

“Post weaning diarrhea is one of the biggest challenges in the global pork industry. We are very excited to join this partnership with Bactolife. Together, we will be able to develop innovative biosolutions that can stabilize the gut of piglets, increase productivity, and significantly reduce the use of antibiotic use among weaner pigs,” says Sofie Louise Trads, Director, Animal Health at Novozymes. 

“We are extremely happy to partner with Novozymes on this promising product. This is a major validation of Bactolife’s technology platform, and with a strong commercial partnership in the Animal Health space like Novozymes, we believe there is a significant business potential for both parties,” says Sebastian Søderberg, CEO at Bactolife.”      

 

“Since we started Bactolife, Ablacto+ has been leading the way for our technology platform, validating the impact that highly specific binding proteins can have on complex problems, such as PWD. Ablacto+ will tackle a One Health challenge supporting animal welfare and global health as antibiotics use is reduced and animals remain healthy,” says Sandra Wingaard Thrane, CSO at Bactolife. 

  

Reduces the need for antibiotics

The product candidate, Ablacto+, is a functional feed additive which consists of binding proteins with a specific mode of action. Binding proteins are science-backed, versatile ingredients that significantly reduce the risk of gastrointestinal infections including PWD.

Novozymes and Bactolife believe that their new biosolution with its novel mode of action can be a game changer within reducing antibiotic consumption in pigs and thereby reducing the risk of antibiotic resistance development in both pigs and humans.

ABLACTO+ has already shown promising results in large scale swine trials, and Novozymes and Bactolife will now collaborate to finalize the product development and subsequently commercialize the Ablacto+ product. Novozymes will develop and produce the final product and has the global exclusive marketing and sales responsibility.

Ablacto+ is expected to be launched in 2026.





*DANMAP 2021: https://www.danmap.org/reports/2021

About Bactolife A/S

Bactolife is a Danish industrial biotech company. Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting growth or killing the bacteria directly. The company is developing and will market ingredients for Mothers & Children, Elderly, Immunodeficient, Travelers & Deployed and Animal Health. www.bactolife.com 

Contact: 
Julie Rastad,
SVP Business Development, Marketing and Communication,
Phone: +4530770262

jlr@bactolife.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15 billion turnover • 30+ industries • 700+ products

Get in touch

Media relations

Lina Danstrup

Lina Danstrup

Head of External Communicationlind@novozymes.com+45 30 77 05 52

Related articles

Novonesis HQ in Lyngby, Denmark
01.02.24 | 8 minute read

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.
Novonesis office
29.01.24 | 6 minute read

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet.
Novonesis
13.12.23 | 8 minute read

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis’. Novonesis means ‘A new beginning’ and derives from the Greek word ‘genesis’. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.